New diabetes shot aims to lower blood sugar and weight in 1,100 patients
NCT ID NCT06778967
First seen Jan 05, 2026 · Last updated May 17, 2026 · Updated 21 times
Summary
This study tests a new medicine called GZR18 in about 1,100 Chinese adults with type 2 diabetes whose blood sugar is not well controlled by metformin alone or with other diabetes pills. Participants receive either GZR18 or an active comparator to see which works better at lowering blood sugar and body weight over time. The goal is to find a more effective treatment option for managing diabetes long-term.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES MELLITUS (T2DM) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Tianjin Medical University General Hospital
Tianjin, China
Conditions
Explore the condition pages connected to this study.